natgillin/translations-raw huggingface dataset:
The mean plasma clearance of Kineret in subjects with mild (creatinine clearance 50-80 mL/min) and moderate (creatinine clearance 30-49 mL/min) renal insufficiency was reduced by 16% and 50%, respectively.
Srednji klirens Kinereta u plazmi u bolesnika s blagom insuficijencijom bubrega (klirens kreatinina 50-80 ml/min) bio je manji za 16%, a u onih s umjerenom insuficijencom bubrega (klirens kreatinina 30-49 ml/min) 50% manji.
The mean plasma clearance of Kineret in subjects with mild (creatinine clearance 50-80 mL/min) and moderate (creatinine clearance 30-49 mL/min) renal insufficiency was reduced by 16% and 50%, respectively.
Srednji klirens Kinereta u plazmi u bolesnika s blagom insuficijencijom bubrega (klirens kreatinina 50-80 ml/min) bio je manji za 16%, a u onih s umjerenom insuficijencom bubrega (klirens kreatinina 30-49 ml/min) za 50%.
The mean plasma elimination half-life (t½) is 1.3 hr.
Srednja vrijednost poluvijeka (t½) eliminacije plazme iznosi 1,3 sata.
The mean plasma half-life of Oncaspar was 8 days in non- hypersensitive patients (AUC 10.35 U/ml/day), and 2.7 days in hypersensitive patients (AUC 3.52 U/ml/day).
Srednji poluvijek Oncaspara u plazmi bio je 8 dana u bolesnika bez preosjetljivosti (AUC 10,35 U/ml/dan), odnosno 2,7 dana u preosjetljivih bolesnika (AUC 3,52 U/ml/dan).
The mean platelet count nadir measured was approximately 40% of baseline in the single-agent multiple myeloma studies and 50% in the MCL study.
U ispitivanjima multiplog mijeloma s jednim lijekom najniža izmjerena srednja vrijednost broja trombocita bila je približno 40% početne vrijednosti a 50% u ispitivanju limfoma plaštenih stanica .
The mean postural changes in systolic and diastolic blood pressure over time were small (< 10 mmHg) and returned towards baseline beyond 2 hours.
Srednje vrijednosti posturalne promjene sistoličkog i dijastoličkog krvnog tlaka tijekom vremena su bile male (< 10 mmHg) i vratile su se prema početnim vrijednostima nakon 2 sata.
The mean pre-dose FEV1 (average of the values taken at -45 and -15 minutes prior to the morning dose of study medication) was statistically significant in favour of Ultibro Breezhaler at week 26 compared to fluticasone/salmeterol (100 ml, p<0.001), at week 52 compared to placebo (189 ml, p<0.001) and at all visits up to week 64 compared to glycopyrronium (70-80 ml, p<0.001) and tiotropium (60-70 ml, p<0.001).
Srednji FEV1 prije doze (prosjek vrijednosti izmjerenih -45 i -15 minuta prije jutarnje doze ispitivanog lijeka) bio je statistički značajan u korist Ultibro Breezhalera u 26 tjednu u usporedbi s flutikazonom/salmeterolom (100 ml, p<0,001), u 52 tjednu u usporedbi s placebom (189 ml, p<0,001) i na svim posjetima do 64. tjedna u usporedbi s glikopironijem (70-80 ml, p<0,001) i tiotropijem (60-70 ml, p <0,001).
The mean pre-dose FEV1 (average of the values taken at -45 and -15 minutes prior to the morning dose of study medication) was statistically significant in favour of Ulunar Breezhaler at week 26 compared to fluticasone/salmeterol (100 ml, p<0.001), at week 52 compared to placebo (189 ml, p<0.001) and at all visits up to week 64 compared to glycopyrronium (70-80 ml, p<0.001) and tiotropium (60-70 ml, p<0.001).
Srednji FEV1 prije doze (prosjek vrijednosti izmjerenih -45 i -15 minuta prije jutarnje doze ispitivanog lijeka) bio je statistički značajan u korist Ulunar Breezhalera u 26 tjednu u usporedbi s flutikazonom/salmeterolom (100 ml, p<0,001), u 52 tjednu u usporedbi s placebom (189 ml, p<0,001) i na svim posjetima do 64. tjedna u usporedbi s glikopironijem (70-80 ml, p<0,001) i tiotropijem (60-70 ml, p <0,001).
The mean pre-dose FEV1 (average of the values taken at -45 and -15 minutes prior to the morning dose of study medication) was statistically significant in favour of Xoterna Breezhaler at week 26 compared to fluticasone/salmeterol (100 ml, p<0.001), at week 52 compared to placebo (189 ml, p<0.001) and at all visits up to week 64 compared to glycopyrronium (70-80 ml, p<0.001) and tiotropium (60-70 ml, p<0.001).
Srednji FEV1 prije doze (prosjek vrijednosti izmjerenih -45 i -15 minuta prije jutarnje doze ispitivanog lijeka) bio je statistički značajan u korist Xoterna Breezhalera u 26 tjednu u usporedbi s flutikazonom/salmeterolom (100 ml, p<0,001), u 52 tjednu u usporedbi s placebom (189 ml, p<0,001) i na svim posjetima do 64. tjedna u usporedbi s glikopironijem (70-80 ml, p<0,001) i tiotropijem (60-70 ml, p <0,001).
The mean PUA at baseline was 9.8 mg/dl.
Srednja vrijednost PUA na početku je iznosila 9,8 mg/dl.
The mean rate of BMD gain was less in the tenofovir disoproxil fumarate group compared to the placebo group.
Srednja vrijednost brzine rasta BMD-a bila je manja u skupini koja je primala tenofovirdizoproksilfumarat u usporedbi sa skupinom koja je primala placebo.
The mean rate of lumbar spine bone gain at week 48 was similar between the tenofovir disoproxil fumarate treatment group and the stavudine or zidovudine treatment group.
Srednja vrijednost brzine povećanja koštane mase lumbalne kralježnice u 48. tjednu u skupini liječenoj tenofovirdizoproksilfumaratom bila je slična onoj u skupini liječenoj stavudinom ili zidovudinom.
The mean rate of treatment-requiring bleeds was determined to 0.151 per subject year.
Utvrđena prosječna stopa krvarenja za koje je potrebno liječenje iznosila je 0,151 ispitanika-godina.
The mean ratio of CSF/serum lamivudine concentrations 2-4 hours after oral administration was approximately 12%.
Srednji omjer koncentracija lamivudina u likvoru i serumu 2-4 sata nakon peroralne primjene iznosi oko 12%.
The mean reduction from baseline in IOP ranged from 7.1 to 8.2 mmHg as summarised in Table 3.
Prosječni učinak sniženja od početnog intraokularnog tlaka bio je od 7,1 do 8,2 mmHg kako je prikazano u Tabeli 3.
The mean reduction in the “off” time was 2.5 hours in the rotigotine arm, 2.8 hours in the pramipexole arm and 0.9 hours in the placebo arm.
Vrijeme trajanja off razdoblja u prosjeku je skraćeno za 2,5 h u rotigotin-skupini, za 2,8 h u pramipeksol-skupini, a u placebo-skupini za 0,9 h.
The mean relative change in LDL cholesterol was -3.5% for orlistat 60 mg (baseline 3.30 mmol/l) and +3.8% for placebo (baseline 3.41 mmol/l).
Srednja relativna promjena razine LDL-kolesterola iznosila je -3,5 % za orlistat 60 mg (početna vrijednost 3,30 mmol/l), a +3,8 % za placebo (početna vrijednost 3,41 mmol/l).
The mean relative change in LDL cholesterol was -3.5% for orlistat 60 mg (baseline 3.30 mmol/l) and +3.8% for placebo (baseline 3.41 mmol/l).
Srednja relativna promjena razine LDL-kolesterola iznosila je -3,5% za orlistat 60 mg (početna vrijednost 3,30 mmol/l), a +3,8 % za placebo (početna vrijednost 3,41 mmol/l).
The mean relative change in total cholesterol was -2.4% for orlistat 60 mg (baseline 5.20 mmol/l) and +2.8% for placebo (baseline 5.26 mmol/l).
Srednja relativna promjena razine kolesterola iznosila je -2,4 % za orlistat 60 mg (početna vrijednost 5,20 mmol/l), a +2,8 % za placebo (početna vrijednost 5,26 mmol/l).
The mean relative change in total cholesterol was -2.4% for orlistat 60 mg (baseline 5.20 mmol/l) and +2.8% for placebo (baseline 5.26 mmol/l).
Srednja relativna promjena razine kolesterola iznosila je -2,4 % za orlistat 60 mg (početna vrijednost 5,20 mmol/l), a +2,8% za placebo (početna vrijednost 5,26 mmol/l).
The mean residence time is approximately 5 hours.
Prosječno vrijeme zadržavanja je približno 5 sati.
The mean serum sodium concentration at trial entry was 129 mEq/l (range 114 - 136).
Srednja vrijednost koncentracije serumskog natrija na početku ispitivanja bila je 129 mEq/l (raspon 114 - 136).
The mean serum sodium concentration at trial entry was 129 mEq/l (range 114 - 136).
Srednja vrijednost koncentracije serumskog natrija na početku ispitivanja bila je 129mEq/l (raspon 114 - 136).
The mean steady state clearance of peginterferon beta-1a was 4.1 ± 0.4 L/hr.
Srednja vrijednost klirensa peginterferona beta-1a u stanju dinamičke ravnoteže iznosila je 4,1 ± 0,4 l/sat.
The mean steady state plasma amprenavir trough concentration (Cmin) was 2.12 (1.77-2.54) g/ml and AUC0-tau was 39.6 (34.5–45.3) h*g/ml.
Srednja vrijednost koncentracije amprenavira u plazmi pri stanju dinamičke ravnoteže (Cmin) bila je 2,12 (1,77-2,54) g/ml i AUC0-tau bilo je 39,6 (34,5–45,3) h*g/ml.
The mean steady state plasma trough concentration at 24 hours post-dose was equal to or greater than the mean in vitro IC90 value for anti-HIV-1 activity.
Srednja vrijednost najniţe koncentracije u plazmi pri dinamičkoj ravnoteţi 24 sata nakon primjene doze bila je jednaka ili veća od srednje vrijednosti IC90 in vitro za anti-HIV-1 djelovanje.
The mean steady state volume of distribution ranged from 130 to 165 ml/kg, the mean values of clearance ranged from 33.3 to 37.2 ml/h×kg.
Srednji volumen raspodjele u stanju dinamičke ravnoteže kretao se u rasponu od 130 do 165 ml/kg, dok su se srednje vrijednosti klirensa kretale u rasponu od 33,3 do 37,2 ml/h×kg.
The mean steady-state trough concentration at Week 12 through Week 36 were approximately 8 to 10 μg/mL during adalimumab 40 mg every week treatment.
Kada se adalimumab primjenjivao u dozi od 40 mg svaki tjedan, srednja vrijednost najniže koncentracije u stanju dinamičke ravnoteže od 12. do 36. tjedna iznosila je približno 8 do 10 µg/ml.
The mean steady-state trough concentration prior to the morning dose was 5.5 ±
U stanju dinamičke ravnoteže srednja najniža koncentracija prije jutranje doze bila je 5,5 ± 5,4 μg/ml.
The mean steady-state trough concentration prior to the morning dose was 8.1  5.7 g/ml.
Srednja vrijednost najniže koncentracije u stanju dinamičke ravnoteže, prije jutarnje doze, iznosila je 8,1 ± 5,7 μg/ml.
The mean steady-state volume of distribution following intravenous administration of a 12 mg dose of saquinavir was 700 l (CV 39 %).
Prosječan volumen distribucije u stanju dinamičke ravnoteže nakon intravenske primjene 12 mg sakvinavira iznosio je 700 l (CV 39%).
The mean systemic clearance of lamivudine is approximately
Srednja vrijednost sistemskog klirensa lamivudina je približno
The mean systemic clearance of lamivudine is approximately 0.3 l/h/kg.
Srednji sistemski klirens lamivudina je približno 0,3 l/h/kg.
The mean telaprevir Cmax and AUC were 10% and 21% greater, respectively, compared to healthy subjects (see section 4.2).
Prosječna vrijednost Cmax bila je 10% veća, a vrijednost AUC 21% veća od onih u zdravih ispitanika (vidjeti dio 4.2).
The mean terminal elimination half-life (t1/2) was 372 (range 333 to 405) hours.
Prosječni terminalni poluvijek eliminacije (t1/2) iznosio je 372 (raspon 333 do 405) sata.
The mean terminal elimination half-life of paliperidone was 24, 40, and 51 hours in subjects with mild, moderate, and severe renal impairment, respectively, compared with 23 hours in subjects with normal renal function (CrCl ≥ 80 ml/min).
Prosječan poluvijek uklanjanja paliperidona je bio 24, 40 i 51 sat kod ispitanika s blagim, umjerenim i ozbiljnim oštećenjem bubrega u usporedbi s 23 sata kod ispitanika s normalnom bubrežnom funkcijom (CrCl ≥ 80 ml/min).
The mean terminal exponential half- life of lenvatinib is approximately 28 hours.
Srednja vrijednost terminalnog eksponencijalnog poluvijeka lenvatiniba je približno 28 sati.
The mean terminal half-life in adults was approximately 4 to 5 hours from serum and approximately 3.66 hours from urine.
Srednji terminalni poluvijek u odraslih osoba iznosio je približno 4 do 5 sati iz seruma te približno 3,66 sati iz urina.
The mean terminal half-life of vardenafil in patients receiving vardenafil 10 mg orodispersible tablets ranged between 4 – 6 hours.
Raspon srednje vrijednosti poluvijeka vardenafila u bolesnika koji su primali vardenafil 10 mg raspadljive tablete iznosio je između 4 - 6 sati.
The mean terminal half-life of vardenafil in patients receiving vardenafil 10 mg orodispersible tablets ranged between 4 – 6 hours.
Raspon srednje vrijednosti poluvijeka vardenafila u bolesnika koji su primali Vivanza 10 mg raspadljive tablete za usta iznosio je između 4 - 6 sati.
The mean terminal half-life of vardenafil in patients receiving vardenafil 10 mg orodispersible tablets ranged between 4 – 6 hours.
Raspon srednjevrijednosti poluvijeka vardenafila u bolesnika koji su primali vardenafil 10 mg raspadljive tablete za usta iznosio je između 4 - 6 sati.
The mean terminal half-life of vardenafil in patients receiving Vivanza 10 mg orodispersible tablets ranged between 4 – 6 hours.
Raspon srednje vrijednosti poluvvijeka vardenafila u bolesnika koji su primali Vivanza 10 mg raspadljive tablete iznosio je između 4 - 6 sati.
The mean terminal half-life was 12 minutes (range 2 to 33 minutes).
Srednji krajnji poluvijek je 12 minuta (od 2 do 33 minute).
The mean terminal half-lives following intravenous and subcutaneous administration are about 12 h and 30 h, respectively, demonstrating the effect of absorption processes at the injection site.
Srednja vrijednost poluvijeka nakon intravenske i supkutane primjene iznosi približno 12 sati odnosno 30 sati, što pokazuje učinak apsorpcije na mjestu injekcije.
The mean time between shunt palliation and first administration of study medicinal product was 20 days.
Prosječno vrijeme između ugradnje šanta te prve primjene lijeka iz studije biloje 20 dana.
The mean time of ending the Extended Observation Period due to the need for Paget’s re-treatment from the initial dose was longer for zoledronic acid (7.7 years) than for risedronate (5.1 years).
Srednje vrijeme od završetka produljenog perioda praćenja od početne doze, zbog potrebe za ponovnim liječenjem Pagetove bolesti, bilo je diulje za zoledronatnu kiselinu (7,7 godina), nego za risedronat (5,1 godina).
The mean time of ending the Extended Observation Period due to the need for Paget’s re-treatment from the initial dose was longer for zoledronic acid (7.7 years) than for risedronate (5.1 years).
Srednje vrijeme završetka produljenog perioda praćenja zbog potrebe za ponovnim liječenjem Pagetove bolesti od početne doze bilo je dulje za zoledronatnu kiselinu (7,7 godina) nego za risedronat (5,1 godina).
The mean time of ending the Extended Observation Period due to the need for Paget’s re-treatment from the initial dose was longer for zoledronic acid (7.7 years) than for risedronate (5.1 years).
Srednje vrijeme završetka produljenog razdoblja praćenja zbog potrebe za ponovnim liječenjem Pagetove bolesti nakon početne doze bilo je duže u slučaju zoledronatne kiseline (7,7 godina) nego risedronata (5,1 godina).
The mean Tmax for milbemycin A3 and A4 5-oximes was typically 4 hours and the mean elimination half-lives were 33.9 and
Srednji Tmax za milbemicin A3 i A4 5-oksime bio je uobičajena 4 sata, a srednje poluvrijeme eliminacije bilo je 33,9 i 77,2 sata.
The mean Tmax for spinosyns A and D was 4 hours and the mean elimination half-lives ranged between 131 and 135 hours.
Srednji Tmax za spinosine A i D bio je 4 sata, a srednje poluvrijeme eliminacije bilo je u rasponu od 131 do 135 sata.
The mean total AUC of febuxostat increased by approximately 1.8-fold from 7.5 gh/mL in the normal renal function group to 13.2 g.h/mL in the severe renal dysfunction group.
Srednji ukupni AUC febuksostata povećao se za oko 1,8 puta, sa 7,5 gh/ml u skupini s urednom funkcijom bubrega na 13,2 g.h/ml u skupini s teškim oštećenjem funkcije bubrega.
The mean total excretion of the total dose administered within 14 days was about 17% in urine and 57% in faeces.
Prosječno izlučivanje ukupne doze primijenjene unutar 14 dana bilo je 17% urinom i 57% u fecesu.
The mean Vd ranged between 63 – 276 L.
Srednja vrijednost volumena distribucije (Vd) kreće se između 63 – 276 l.
The mean Vd ranged between 63-276 l.
Srednja vrijednost volumena distribucije (Vd) u rasponu je od 63-276 l.
The mean Vd ranged between 63– 276 litres.
Srednji Vd bio je u rasponu od 63 – 276 litara.
The mean volume of distribution after intravenous administration of liraglutide is 0.07 l/kg.
Srednja vrijednost volumena distribucije nakon intravenske primjene liraglutida je 0,07 l/kg.
The mean volume of distribution at steady state of oral naltrexone and bupropion given as naltrexone / bupropion, Vss/F, was 5697 liters and 880 liters, respectively.
Srednja vrijednost volumena distribucije u stanju dinamičke ravnoteže oralnog naltreksona i bupropiona danih kao naltrekson / bupropion, Vss/F, bila je 5697 litara odnosno 880 litara.
The mean volume of distribution following a single intravenous dose of rasagiline is 243 l.
Srednji volumen distribucije nakon jedne intravenske doze razagilina je 243 l.
The mean volume of distribution of cladribine is 9.2 l/kg.
Prosječni volumen raspodjele kladribina je 9,2 l/kg.
The mean volume of distribution was 49.3 ml/kg after intravenous doses of 50 and 100 IU/kg in healthy subjects.
Srednja vrijednost volumena distribucije bila je 49,3 ml/kg nakon intravenske doze od 50 i 100 IU/kg u zdravih ispitanika.
The mean volumes of distribution (Vss) of 7α-thiomethyl-spironolactone and canrenone are approximately 153 litres and 177 litres, respectively.
Prosječne količine distribucije (Vss) 7α – tiometil - spironolaktona i kanrenona su oko 153 litre, odnosno 177 litara.
The mean weekly itch severity scores significantly decreased with a maximum effect around week 12 that was sustained over the 24-week treatment period.
Srednji tjedni rezultati za težinu svrbeža značajno su se smanjili s najvećim učinkom oko 12. tjedna koji se održao tijekom 24-tjednog razdoblja liječenja.
The mean wound size treated with Episalvan in clinical studies in split-thickness skin graft donor site wounds was 40.7 cm² (range 8-300 cm²).
Srednja vrijednost površine rane liječene Episalvanom u kliničkim ispitivanjima rana donorskog mjesta kožnog presatka djelomične debljine iznosila je 40,7 cm² (raspon 8 – 300 cm²).
The mean ± SD Cmax value was 112 ± 29 ng/mL, and the mean AUC was 2740 ± 790 ng•h/mL.
Aritmetička sredina ± SD Cmax vrijednosti bila je 112 ± 29 ng/mL, a aritmetička sredina AUC-a bila je 2740 ± 790 ng•h/mL.
The mean ± SD EC50 of sofosbuvir against chimeric replicons encoding NS5B sequences from clinical isolates was 0.068 ± 0.024 μM for genotype 1a (n = 67),
Srednja vrijednost ± SD EC50 sofosbuvira za kimerične replikone koji kodiraju sekvence NS5B iz kliničkih izolata iznosila je 0,068 ± 0,024 μM za genotip 1a (n = 67),
The mean ±standard deviation (SD) dissociation constant (Kd) of binding was 5.1 ± 3.0 ng/ml, denoting the concentration at which 50% of binding sites in blood cells were occupied.
Srednja ± standardna devijacija (SD) konstante disocijacije (Kd) vezanja iznosila je 5,1 ± 3,0 ng/ml, pokazujući koncentraciju pri kojoj je 50% mjesta vezanja u krvnim stanicama bilo zauzeto.
The measure of effectiveness in the studies was based on the assessment by the dog owner of the severity of the pruritus and improvements in the dog’s behaviour using a standard scale.
Mjera djelotvornosti u ovim ispitivanjima temelji se na procijeni vlasnika psa o ozbiljnosti pruritusa i poboljšanju ponašanja psa na temelju standardne ljestvice.
The measure of effectiveness was reduction in the number of eggs in their faeces.
Mjera djelotvornosti bilo je smanjenje u broju jajašca u njihovom izmetu.
The measure of effectiveness was reduction in the number of fleas and ticks at day 30 after treatment.
Mjera djelotvornosti bilo je smanjenje u broju buha i krpelja 30. dana nakon terapije.
The measure of effectiveness was reduction of flea and tick counts.
Mjera djelotvornosti bilo je smanjenje broja buha i krpelja.
The measure of effectiveness was reduction of flea counts.
Mjera djelotvornosti bilo je smanjenje broja buha.
The measure of effectiveness was reduction of flea counts.
Mjera djelotvornosti bilo je smanjenje u broju buha.
The measure of effectiveness was reduction of heartworm counts from the heart and lungs of the dogs after 6 months.
Mjera djelotvornosti bilo je smanjenje broja srčanih crva iz srca i pluća pasa nakon 6 mjeseci.
The measure of effectiveness was reduction of the number of mites found in skin scrapings compared to cats that received no treatment.
Mjera djelotvornosti bila je smanjenje broja šugaraca u strugotinama kože u usporedbi s mačkama koje nisu bile liječene.
The measure of effectiveness was success rate based on the proportion of dogs with a reduction in the number of worm eggs in their faeces of 90% or more.
Mjera djelotvornosti temeljila se na udjelu pasa sa smanjenjem broja jajašca crva u izmetu pasa od 90% ili više.
The measure of effectiveness was the ability of the vaccine to trigger the production of antibodies against the Japanese encephalitis virus, four weeks after the final injection.
Mjerilo djelotvornosti bila je sposobnost cjepiva da aktivira stvaranje protutijela protiv virusa japanskog encefalitisa četiri tjedna nakon posljednje injekcije.
The measure of effectiveness was the absence of eggs in the faeces of the animals.
Mjera djelotvornosti bilo je odsustvo jaja nematoda u izmetu životinja.
The measure of effectiveness was the absence of heartworm up to six months after the last treatment.
Mjera djelotvornosti bio je izostanak srčanog crva do šest mjeseci nakon terapije.
The measure of effectiveness was the reduction of intestinal worms in a representative number of chickens.
Mjera djelotvornosti bilo je smanjenje gastrointestinalnih crva kod reprezentativnog broja kokoši.
The measured MMAD of the aerosol droplets was micrometres.
Izmjereni medijan mase aerodinamičkog promjera kapljica aerosola iznosio je 2,6 mikrometara.
The measurement of protein C activity using chromogenic substrates is recommended for the determination of the patient’s plasma level for protein C before and during treatment with CEPROTIN.
Za određivanje razine proteina C u plazmi pacijenta prije i tijekom liječenja lijekom CEPROTIN preporučuje se mjerenje aktivnosti proteina C korištenjem kromogenog supstrata.
The measurement of protein C activity using chromogenic substrates is recommended for the determination of your plasma level for protein C before and during treatment with CEPROTIN.
Za određivanje razine proteina C u plazmi prije i tijekom liječenja lijekom CEPROTIN preporučuje se mjerenje aktivnosti proteina C korištenjem kromogenog supstrata
The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV, and for the non-enveloped viruses HAV and parvovirus B19.
Navedene mjere smatraju se učinkovitima za viruse s ovojnicom kao što su HIV, HBV i HCV i za viruse bez ovojnice kao što su HAV i parvovirus B19.
The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV, and for the non-enveloped viruses HAV and parvovirus B19.
Poduzete mjere smatraju se učinkovitim za viruse s ovojnicom poput HIV-a, HBV-a i HCV-a te za viruse koji nemaju ovojnicu kao što su HAV i parvovirus B19.
The measures taken are considered effective for enveloped viruses such as HIV, hepatitis C virus, and hepatitis B virus, and for the non-enveloped hepatitis A virus.
Poduzete mjere smatraju se učinkovitima protiv virusa s lipidnom ovojnicom poput HIV-a, virusa hepatitisa C i virusa hepatitisa B, te protiv virusa hepatitisa A koji je bez ovojnice.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), and for the non-enveloped hepatitis A virus (HAV).
Poduzete mjere smatraju se djelotvornim za viruse s ovojnicom poput virusa humane imunodeficijencije (HIV), virusa hepatitisa B (HBV) i hepatitisa C (HCV) te za viruse hepatitisa A
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), and for the non-enveloped hepatitis A virus (HAV).
Poduzete mjere smatraju se djelotvornim za viruse s ovojnicom poput virusa humane imunodeficijencije (HIV), virusa hepatitisa B (HBV) i hepatitisa C (HCV) te za viruse hepatitisa A “bez ovojnice“ (HAV).